Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

REC 617 - Recursion Pharmaceuticals

Next Previous
Drug Profile

REC 617 - Recursion Pharmaceuticals

Alternative Names: '617; EXS-617; GTAEXS-617; REC-617- Recursion

Latest Information Update: 13 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GT Apeiron Therapeutics
  • Developer GT Apeiron Therapeutics; Recursion Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Cyclin-dependent kinase-activating kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 05 May 2025 Recursion Pharmaceuticals plans to initiate a clinical trial for Solid tumours (In combination therapy) in First half of 2025
  • 13 Dec 2024 Efficacy, adverse event, pharmacokinetics and pharmacodynamics data from the phase I/II trial in Solid tumours released by Recursion
  • 20 Nov 2024 Exscientia has been acquired and merged into Recursion Pharmaceuticals

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top